Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno-associated virus gene therapy to correct an underlying genetic defect. The diseases that Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neur... Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno-associated virus gene therapy to correct an underlying genetic defect. The diseases that Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). Show more
REGENXBIO to Participate in Chardan's 8th Annual Genetic Medicines Conference PR Newswire ROCKVILLE, Md., Sept. 23, 2024 ROCKVILLE, Md., Sept. 23, 2024 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq:...
REGENXBIO Appoints Mitchell Chan as Chief Financial Officer PR Newswire ROCKVILLE, Md., Sept. 17, 2024 Life sciences veteran Mitchell Chan joins the company ahead of multiple catalysts across...
REGENXBIO Announces Positive Data from Pivotal Dose Level of RGX-121 Demonstrating Long-Term Systemic Effect PR Newswire ROCKVILLE, Md., Sept. 3, 2024 - Data from pivotal dose level demonstrates...
REGENXBIO to Participate in Upcoming Investor Conferences PR Newswire ROCKVILLE, Md., Aug. 29, 2024 ROCKVILLE, Md., Aug. 29, 2024 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it...
REGENXBIO Announces Presentation at the Society for the Study of Inborn Errors of Metabolism (SSIEM) 2024 Annual Symposium PR Newswire ROCKVILLE, Md., Aug. 27, 2024 ROCKVILLE, Md., Aug. 27, 2024...
REGENXBIO to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference PR Newswire ROCKVILLE, Md., Aug. 8, 2024 ROCKVILLE, Md., Aug. 8, 2024 /PRNewswire/ -- REGENXBIO Inc...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -1.21 | -9.39440993789 | 12.88 | 13.48 | 11.56 | 793262 | 12.32820937 | CS |
4 | -0.61 | -4.9674267101 | 12.28 | 13.48 | 11.08 | 491394 | 12.01239104 | CS |
12 | -0.01 | -0.0856164383562 | 11.68 | 15.36 | 10.49 | 491246 | 12.41825784 | CS |
26 | -10.14 | -46.492434663 | 21.81 | 22.42 | 10.49 | 501824 | 13.96772482 | CS |
52 | -5.34 | -31.39329806 | 17.01 | 28.8 | 10.49 | 572412 | 16.27203837 | CS |
156 | -31.66 | -73.0671590122 | 43.33 | 44.4 | 10.49 | 452081 | 21.42322116 | CS |
260 | -27.98 | -70.5674653216 | 39.65 | 54.97 | 10.49 | 440809 | 27.8688224 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.